Craig Johnstone

“So to your question about the balance, and it's a very good question, the balance between the impact of reset and reduction in roles and capacity while retaining our need and our edge in technology.”

“No. Only just to reemphasize that there are a number of components in the shared R&D offering, which are highly differentiated, highly attractive and doing extraordinarily well.”

“Regarding the pie chart, your understanding is correct, and it highlights the area most affected by the cyberattack. There are two key aspects to consider. Firstly, from a cost perspective, the Execute segment carries the majority of the group's fixed expenses, including buildings, personnel, and infrastructure.”

“It's important to remember we are still in a build-out and ramp-up phase; the whole design of the Just – Evotec Biologics concept allows for modular expansion. We are not fully utilizing our capacity as it stands today.”

“You're, of course, right that the revenues have been going down during the quarter, and it looks like a trajectory. But as you also have seen and heard, the amount of sales that we've recognized during the course of 2022 has tremendously increased over 2021.”